Effects of Danshen constituent Tanshinone IIA on tumor vasculature
丹参成分丹参酮IIA对肿瘤血管的影响
基本信息
- 批准号:7790203
- 负责人:
- 金额:$ 15.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAnti-Inflammatory AgentsAnti-inflammatoryAnticoagulantsAntineoplastic AgentsAntioxidantsApoptosisAsiansBiologicalBloodBlood VesselsBlood flowCardiovascular systemCell DeathCell LineCell SurvivalCell physiologyChemicalsChinaChinese HerbsChinese Traditional MedicineClinicalCountryDiseaseDiterpenesDoxorubicinElectronsEndothelial CellsFluorescenceGoalsHerbHerbal MedicineHumanImageInflammatoryLeadLifeLightMalignant NeoplasmsMicroscopicModelingMorphologyNeoplasms in Vascular TissuePharmaceutical PreparationsPlayProstatic NeoplasmsReportingRoleSalvia miltiorrhizaStructureSwellingTestingTherapeuticTherapeutic EffectTimeTissuesTranslationsTubeUltrasonographyVascular DiseasesVascular Systemcancer therapychemotherapeutic agentcytochrome ccytotoxicityfluorescence imagingimaging modalitymigrationneoplastic cellpublic health relevancetheoriestumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Danshen (Radix Salvia miltiorrhiza), one of the most important herbal drugs in traditional Chinese medicine, is widely used for the treatment of cardiovascular, inflammatory and cancer diseases in China and some other Asian countries. Being a major biologically active constituent isolated from Danshen, tanshinone IIA (Tan IIA), a diterpenoid, is found to be responsible for many of the actions of Danshen. In addition to antioxidant, anti-inflammatory and anticoagulant activities, Tan IIA has been shown to induce tumor cell death and inhibit tumor growth. However, the mechanism responsible for its anticancer effect is still poorly understood. Since tumor vasculature plays an important role in tumor growth and progression, and Danshen as well as its constituent Tan IIA are well-known to treat vascular diseases, it is hypothesize that Tan IIA may modify tumor vascular function to inhibit tumor growth. This hypothesis is further supported by recent studies from our lab and other groups indicating that Tan IIA is able to induce endothelial cell apoptosis through triggering cytochrome c release. So far there is no report studying the effect of Tan IIA on tumor vasculature. Thus, one goal of this proposed study is to determine whether Tan IIA can modify tumor vascular structure and function, leading to tumor regression. Since Danshen is usually used in combination with other Chinese herbs or conventional chemotherapeutic agents in the treatment of cancer, the other goal of this study is to determine whether Tan IIA is able to enhance the delivery and effects of other anticancer agents through modifying tumor vascular function. The specific aims of this proposal are to: (1) determine the effects of Tan IIA on endothelial cell viability, morphology and function, (2) determine the effects of Tan IIA on tumor vascular structure and function, (3) determine the effects of Tan IIA on the delivery and effect of anticancer drug. Multi-modality imaging including live animal imaging (i.e. intravital fluorescence imaging, whole body fluorescence imaging and ultrasound imaging) together with static ex vivo imaging (i.e. light, fluorescence and electron microscopic imaging) will be used complementarily to determine the effects of Tan IIA on tumor vasculature and whether Tan IIA can enhance the delivery and therapeutic effect of chemotherapeutic agent doxorubicin. Results from this study will help understand the anticancer mechanism of Chinese herb Danshen and contribute to the clinical translation of this herbal molecule as a tumor vascular-targeting agent.
PUBLIC HEALTH RELEVANCE: This study will determine whether tanshinone IIA, a major active constituent of Chinese herbal medicine Danshen, is able to target tumor vasculature and enhance the antitumor effect of chemotherapeutic agent. Results from this study will lead to a better understanding of anticancer mechanisms of Danshen.
描述(申请人提供): 丹参(Radix Salvia miltiorriza)是传统中药中最重要的草药之一,在中国和其他一些亚洲国家广泛用于治疗心血管、炎症和癌症疾病。丹参酮 IIA (Tan IIA) 是一种二萜类化合物,是从丹参中分离出来的主要生物活性成分,被发现与丹参的许多作用有关。除了抗氧化、抗炎和抗凝血活性外,Tan IIA 还被证明可以诱导肿瘤细胞死亡并抑制肿瘤生长。然而,其抗癌作用的机制仍知之甚少。由于肿瘤血管系统在肿瘤生长和进展中发挥着重要作用,而丹参及其成分 Tan IIA 众所周知可以治疗血管疾病,因此推测 Tan IIA 可能会改变肿瘤血管功能以抑制肿瘤生长。我们实验室和其他小组最近的研究进一步支持了这一假设,表明 Tan IIA 能够通过触发细胞色素 c 释放来诱导内皮细胞凋亡。目前尚未见Tan IIA对肿瘤血管影响的研究报道。因此,这项研究的目标之一是确定 Tan IIA 是否可以改变肿瘤血管结构和功能,从而导致肿瘤消退。由于丹参通常与其他中药或常规化疗药物联合使用来治疗癌症,因此本研究的另一个目标是确定丹参IIA是否能够通过改变肿瘤血管功能来增强其他抗癌药物的递送和效果。该提案的具体目的是:(1)确定Tan IIA对内皮细胞活力、形态和功能的影响,(2)确定Tan IIA对肿瘤血管结构和功能的影响,(3)确定Tan IIA对抗癌药物的递送和效果的影响。多模态成像包括活体动物成像(即活体荧光成像、全身荧光成像和超声成像)与静态离体成像(即光、荧光和电子显微镜成像)相结合,将互补使用以确定Tan IIA对肿瘤血管系统的影响以及Tan IIA是否可以增强化疗药物的递送和治疗效果 阿霉素。这项研究的结果将有助于了解中草药丹参的抗癌机制,并有助于该草药分子作为肿瘤血管靶向剂的临床转化。
公共健康相关性:本研究将确定中草药丹参的主要活性成分丹参酮 IIA 是否能够靶向肿瘤血管系统并增强化疗药物的抗肿瘤效果。这项研究的结果将有助于更好地了解丹参的抗癌机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BIN CHEN其他文献
BIN CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BIN CHEN', 18)}}的其他基金
Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment
荧光引导肿瘤切除和治疗中氨基乙酰丙酸-原卟啉 IX 的优化
- 批准号:
10818914 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment
荧光引导肿瘤切除和治疗中氨基乙酰丙酸-原卟啉 IX 的优化
- 批准号:
10360122 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment
荧光引导肿瘤切除和治疗中氨基乙酰丙酸-原卟啉 IX 的优化
- 批准号:
10705406 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment
荧光引导肿瘤切除和治疗中氨基乙酰丙酸-原卟啉 IX 的优化
- 批准号:
9516530 - 财政年份:2018
- 资助金额:
$ 15.5万 - 项目类别:
Effects of Danshen constituent Tanshinone IIA on tumor vasculature
丹参成分丹参酮IIA对肿瘤血管的影响
- 批准号:
8037157 - 财政年份:2010
- 资助金额:
$ 15.5万 - 项目类别:
DIFFUSION TENSOR MICROSCOPY OF STAINED MOUSE BRAIN
染色小鼠大脑的扩散张量显微镜
- 批准号:
7358242 - 财政年份:2006
- 资助金额:
$ 15.5万 - 项目类别:
DIFFUSION TENSOR MICROSCOPY OF STAINED MOUSE BRAIN
染色小鼠大脑的扩散张量显微镜
- 批准号:
7181509 - 财政年份:2005
- 资助金额:
$ 15.5万 - 项目类别:
DIFFUSION TENSOR MICROSCOPY OF STAINED MOUSE BRAIN
染色小鼠大脑的扩散张量显微镜
- 批准号:
6977795 - 财政年份:2004
- 资助金额:
$ 15.5万 - 项目类别:
Identifying Genes Involved in Neuronal Differentiation
鉴定参与神经元分化的基因
- 批准号:
6641141 - 财政年份:2002
- 资助金额:
$ 15.5万 - 项目类别:
Identifying Genes Involved in Neuronal Differentiation
鉴定参与神经元分化的基因
- 批准号:
6529745 - 财政年份:2002
- 资助金额:
$ 15.5万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 15.5万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 15.5万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 15.5万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 15.5万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:














{{item.name}}会员




